TRDA - NASDAQ
Entrada Therapeutics, Inc.
$6.58
-0.90%Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotEntrada Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Entrada Therapeutics, Inc. Balance Sheet
TRDA • NASDAQ
| Entrada Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
90.4M | 101.2M | 67.6M | 45.2M | 291.1M | 39M | 16.8M | |
205.3M | 318.8M | 284.4M | 143.6M | 0.0 | 0.0 | 0.0 | |
295.7M | 420M | 352M | 188.7M | 291.1M | 39M | 16.8M | |
0.0 | 3.7M | 5.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 5.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 7.6M | 904K | 593K | |
10.6M | 16.4M | 11.9M | 21.2M | 0.0 | 0.0 | 0.0 | |
306.3M | 440M | 369.8M | 209.9M | 298.7M | 39.9M | 17.4M | |
NON-CURRENT ASSETS | |||||||
67.8M | 82M | 92.7M | 33M | 6.3M | 3M | 801K | |
3.4M | 4.2M | 6.7M | 9.2M | 872K | 541K | -801K | |
71.1M | 86.3M | 99.4M | 42.2M | 7.1M | 3.6M | 801K | |
377.4M | 526.3M | 469.2M | 252.1M | 305.8M | 43.5M | 18.2M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
2.3M | 4.9M | 7.3M | 6M | 706K | 1.6M | 710K | |
2.3M | 4.3M | 3.3M | 6M | 706K | 1.6M | 710K | |
0.0 | 667K | 4M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 4.9M | 3.7M | 2.1M | 1.5M | 160K | 992K | |
4.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 7.6M | 7.9M | 8.4M | 0.0 | 0.0 | 0.0 | |
0.0 | 667K | 4M | 0.0 | 0.0 | 0.0 | 0.0 | |
342K | 13.7M | 132.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
17.7M | 8.4M | 7.7M | 5.5M | 4.6M | 1.6M | 219K | |
24.5M | 39.5M | 158.8M | 22M | 6.7M | 3.4M | 1.9M | |
NON-CURRENT LIABILITIES | |||||||
46.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 6.5M | 7.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 396K | 81.7M | 31.8M | |
46.8M | 58.2M | 68M | 17.5M | 396K | 81.7M | 31.8M | |
0.0 | 59.2M | 68.2M | 25.9M | 0.0 | 0.0 | 0.0 | |
71.2M | 97.6M | 226.8M | 39.5M | 7.1M | 85M | 33.8M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.8M | |
4K | 4K | 3K | 3K | 3K | 0.0 | 1K | |
0.0 | 558.1M | 437.1M | 402.9M | 392.4M | 1M | 469K | |
-273.1M | -129.3M | -195M | -188.3M | -93.7M | -42.5M | -16M | |
652K | -43K | 195K | -2.1M | 0.0 | 0.0 | -31.8M | |
578.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 31.8M | |
306.1M | 428.7M | 242.4M | 212.6M | 298.7M | -41.5M | -15.5M | |
306.1M | 428.7M | 242.4M | 212.6M | 298.7M | -41.5M | -15.5M | |
SUMMARY | |||||||
377.4M | 526.3M | 469.2M | 252.1M | 305.8M | 43.5M | 18.2M | |
205.3M | 318.8M | 284.4M | 143.6M | 0.0 | 0.0 | 0.0 | |
50.9M | 59.2M | 68.2M | 25.9M | 0.0 | 0.0 | 0.0 | |
-39.5M | -42M | 628K | -19.2M | -291.1M | -39M | -16.8M | |
38,037,079 | 38,037,079 | 38,037,079 | 38,037,079 | 38,037,079 | 38,037,079 | 38,037,079 |
SEC Filings
TRDA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
S-3 S-3 N/A | November 06, 2025 | November 06, 2025 | ||
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your TRDA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.